

Immunoassay Market based on by Product (Reagents and Kits, Analyzers/Instruments, Software and Services), Technology [Radioimmunoassay (RIA), Enzyme-linked Immunosorbent Assay (ELISA), Enzyme-linked Fluorescent Assay (ELFA), Chemiluminescence Immunoassay (CLIA), Rapid Test, Others], Indication (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Diseases, Autoimmune Diseases, Others), End User (Hospitals, Clinical Laboratories, Blood Banks, Pharmaceutical and Biotechnology Companies, Academic) and Regional Outlook– Global Forecast up to 2030

<https://marketpublishers.com/r/I80C81077EA5EN.html>

Date: November 2023

Pages: 80

Price: US\$ 4,500.00 (Single User License)

ID: I80C81077EA5EN

Abstracts

A significant amount of secondary sources, directories, and databases were used in this market research study in order to locate and gather data relevant to this technical, financial, and market-oriented analysis of the worldwide biomarkers market. In order to gather and validate crucial qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were carried out with a variety of primary respondents, including important industry participants, subject-matter experts (SMEs), C-level executives of significant market players, and industry consultants, among other experts. To get the ultimate market size, the worldwide biomarkers market's size—which was approximated using a variety of secondary research techniques—was triangulated with data from primary research.

An immunoassay is a biochemistry-based test used to determine if an analyte is present or concentrated. A big protein or antibody that is created as a result of an infection can be an analyte. Immunoassays are now widely used and recognised laboratory protocols. They deliver exact and accurate results fast and effortlessly. The main applications of this approach are in food testing, drug discovery, clinical diagnostics, and drug monitoring.

The market was divided into a number of segments and sub-segments once the overall market size was determined utilising the market size estimation procedures. Data triangulation and market breakdown processes were used when appropriate to finish the entire market engineering process and obtain the precise statistics of each market segment and subsegment. By examining numerous variables and patterns from the immunoassays industry's supply and demand sides, the data was triangulated.

Immunoassay Market based on Technology:

ELISA

Fluorescence

Colorimetric

Chemiluminescence

Rapid Test

Western Blot

ELISPOT

PCR

Immunoassay Market based on Product & Service:

Reagents & Kits

Analyzers

Software Services

Immunoassay Market based on Application:

Infectious Disease

Endocrinology

Cardiology

Oncology

Hematology

Immunoassay Market based on End User:

Hospitals

Clinical Laboratories

Blood Banks

Academic Research Centers

Pharmaceutical Companies

Biotechnology Companies

Others

Immunoassay Market based on Geography:

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe (RoE)

Asia Pacific (APAC)

China

Japan

India

Australia

South Korea

Rest of Asia Pacific (RoAPAC)

Latin America (LATAM)

Brazil

Argentina

Rest of South America

Middle East and Africa (MEA)

UAE

Turkey

Saudi Arabia

South Africa

Rest of Middle East & Africa

The market for immunoassay has expanded significantly as a result of technology developments. For quicker testing and outcomes, automated laboratory apparatus has been designed. Labour and space requirements are decreased and laboratory efficiency is increased by automation. Because some players provide small, portable automated laboratory systems and point-of-care testing, the industry is growing quickly as a result.

Research laboratories, especially biotechnology labs, should catch up with their counterparts in diagnostics in terms of automated immunoassay implementation, and they should also become more familiar with the development of diagnostic apparatus. Every industry, including healthcare, is becoming more automated. Automated immunoassays, for example, offer increased assay transfer, reproducibility, and throughput.

Reduction in time and operator dependence on unpredictability are the two benefits of this method. In the US, Siemens Healthcare Diagnostic, for example, provides five completely automated immunoassay platforms.

In 2022, the immunoassay market was dominated by the kit and reagent category, which held a market share of over 61%. During the projected period, the sector is anticipated to lead the market. There is a growing need for immunoassay kits and reagents for diagnostic applications due to the rising incidence of autoimmune and infectious disorders. Additionally, immunoassay kit approval and distribution are anticipated to support segment expansion.

In 2022, the immunoassay market was dominated by the ELISA category, which held a

market share of over 61%. This method has several advantages over immunoelectrophoretic and immunodiffusion, such as antiserum analysis, faster test periods, and qualitative and qualitative results.

The rising incidence of cancer cases around the world is the main reason boosting the immunoassay market over the predicted period. The International Agency for Research on Cancer projected that there will be over 18.2 million new cases of cancer worldwide in 2020, and that the disease will cause over 10 million deaths. Therefore, it is anticipated that a rise in cancer incidence will increase the use of immunoassays.

The immunoassay market is divided into end-user segments based on the following: blood banks, clinical labs, pharmaceutical & biotechnology firms, hospitals & clinics, research & academic laboratories, CROs, and home care settings. With a 31% market share in 2022, the hospital & clinical segment will have a dominant position in the immunoassay industry. The hospital segment is growing quickly as a result of the rise in hospital numbers.

This report illustrates the most vital attributes of the Immunoassay Market, which are driving and providing opportunities.

This research gives an in-depth analysis of the Immunoassay Market growth on the basis of several segments in the market.

This report presents the predictions of the past and present trends of the Biomarkers Market.

This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Immunoassay Market.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

- 2.1. Industry Overview
- 2.2. Industry Trends

3. MARKET SNAPSHOT

- 3.1. Market Definition
- 3.2. Market Outlook
 - 3.2.1. Porter Five Forces
- 3.3. Related Markets

4. MARKET CHARACTERISTICS

- 4.1. Market Overview
- 4.2. Market Segmentation
- 4.3. Market Dynamics
 - 4.3.1. Drivers
 - 4.3.2. Restraints
 - 4.3.3. Opportunities
- 4.4. DRO - Impact Analysis

5. PRODUCT TYPE: MARKET SIZE & ANALYSIS

- 5.1. Overview
- 5.2. Consumables
- 5.3. Services
- 5.4. Software

6. TECHNOLOGY: MARKET SIZE & ANALYSIS

- 6.1. Overview
- 6.2. Safety Biomarkers
- 6.3. Efficacy Biomarkers

- 6.4. Predictive Biomarkers
- 6.5. Surrogate Biomarkers
- 6.6. Pharmacodynamics Biomarkers
- 6.7. Prognostic Biomarkers
- 6.8. Validation Biomarkers

7. PRODUCT & SERVICE: MARKET SIZE & ANALYSIS

- 7.1. Overview
- 7.2. Safety Biomarkers
- 7.3. Efficacy Biomarkers
- 7.4. Predictive Biomarkers
- 7.5. Surrogate Biomarkers
- 7.6. Pharmacodynamics Biomarkers
- 7.7. Prognostic Biomarkers
- 7.8. Validation Biomarkers

8. APPLICATION: MARKET SIZE & ANALYSIS

- 8.1. Overview
- 8.2. ELISA
- 8.3. Fluorescence
- 8.4. Colorimetric
- 8.5. Chemiluminescence
- 8.6. Rapid Test
- 8.7. Western Blot
- 8.8. ELISPOT
- 8.9. PCR

9. END USER: MARKET SIZE & ANALYSIS

- 9.1. Overview
- 9.2. Hospitals
- 9.3. Clinical Laboratories
- 9.4. Blood Banks
- 9.5. Academic Research Centers
- 9.6. Pharmaceutical Companies
- 9.7. Biotechnology Companies
- 9.8. Others

10. GEOGRAPHY: MARKET SIZE & ANALYSIS

10.1. Overview

10.2. North America (U.S., Mexico, Canada)

10.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)

10.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)

10.5. Latin America (Brazil, Argentina)

10.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)

11. COMPETITIVE LANDSCAPE

11.1. Competitor Comparison Analysis

11.2. Market Developments

11.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

11.2.2. Product Launches and execution

12. VENDOR PROFILES

12.1. Siemens Healthineers

12.1.1. Overview

12.1.2. Financial Overview

12.1.3. Product Offerings

12.1.4. Developments

12.1.5. Business Strategy

12.2. bioMérieux SA

12.2.1. Overview

12.2.2. Financial Overview

12.2.3. Product Offerings

12.2.4. Developments

12.2.5. Business Strategy

12.3. Abbott Laboratories

12.3.1. Overview

12.3.2. Financial Overview

12.3.3. Product Offerings

12.3.4. Developments

12.3.5. Business Strategy

12.4. Danaher Corporation (Beckman Coulter)

- 12.4.1. Overview
- 12.4.2. Financial Overview
- 12.4.3. Product Offerings
- 12.4.4. Developments
- 12.4.5. Business Strategy
- 12.5. Quidel Corporation
 - 12.5.1. Overview
 - 12.5.2. Financial Overview
 - 12.5.3. Product Offerings
 - 12.5.4. Developments
 - 12.5.5. Business Strategy
- 12.6. Ortho Clinical Diagnostics
 - 12.6.1. Overview
 - 12.6.2. Financial Overview
 - 12.6.3. Product Offerings
 - 12.6.4. Developments
 - 12.6.5. Business Strategy
- 12.7. Sysmex Corporation
 - 12.7.1. Overview
 - 12.7.2. Financial Overview
 - 12.7.3. Product Offerings
 - 12.7.4. Developments
 - 12.7.5. Business Strategy
- 12.8. Bio-Rad Laboratories, Inc.
 - 12.8.1. Overview
 - 12.8.2. Financial Overview
 - 12.8.3. Product Offerings
 - 12.8.4. Developments
 - 12.8.5. Business Strategy
- 12.9. F. Hoffmann-La Roche AG
 - 12.9.1. Overview
 - 12.9.2. Financial Overview
 - 12.9.3. Product Offerings
 - 12.9.4. Developments
 - 12.9.5. Business Strategy
- 12.10. Thermo Fisher Scientific, Inc.
 - 12.10.1. Overview
 - 12.10.2. Financial Overview
 - 12.10.3. Product Offerings

- 12.10.4. Developments
- 12.10.5. Business Strategy

13. ANALYST OPINION

14. ANNEXURE

- 14.1. Report Scope
- 14.2. Market Definitions
- 14.3. Research Methodology
 - 14.3.1. Data Collation and In-house Estimation
 - 14.3.2. Market Triangulation
 - 14.3.3. Forecasting
- 14.4. Report Assumptions
- 14.5. Declarations
- 14.6. Stakeholders
- 14.7. Abbreviations

Tables

TABLE 1. IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 2. IMMUNOASSAY MARKET VALUE FOR ELISA, BY GEOGRAPHY , 2021-2030 (USD BILLION)

TABLE 3. IMMUNOASSAY MARKET VALUE FOR FLUORESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 4. IMMUNOASSAY MARKET VALUE FOR COLORIMETRIC, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 5. IMMUNOASSAY MARKET VALUE FOR CHEMILUMINESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 6. IMMUNOASSAY MARKET VALUE FOR RAPID TEST, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 7. IMMUNOASSAY MARKET VALUE FOR WESTERN BLOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 8. IMMUNOASSAY MARKET VALUE FOR ELISPOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 9. IMMUNOASSAY MARKET VALUE FOR PCR, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 10. IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)

TABLE 11. IMMUNOASSAY MARKET VALUE FOR REAGENTS & KITS, 2021-2030 (USD BILLION)

TABLE 12. IMMUNOASSAY MARKET VALUE FOR ANALYZERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 13. IMMUNOASSAY MARKET VALUE FOR SOFTWARE SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 14. IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 15. IMMUNOASSAY MARKET VALUE FOR INFECTIOUS DISEASE, 2021-2030 (USD BILLION)

TABLE 16. IMMUNOASSAY MARKET VALUE FOR ENDOCRINOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 17. IMMUNOASSAY MARKET VALUE FOR CARDIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 18. IMMUNOASSAY MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 19. IMMUNOASSAY MARKET VALUE FOR HEMATOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 20. IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 21. IMMUNOASSAY MARKET VALUE FOR HOSPITALS, 2021-2030 (USD BILLION)

TABLE 22. IMMUNOASSAY MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 23. IMMUNOASSAY MARKET VALUE FOR BLOOD BANKS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 24. IMMUNOASSAY MARKET VALUE FOR ACADEMIC RESEARCH CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 25. IMMUNOASSAY MARKET VALUE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 26. IMMUNOASSAY MARKET VALUE FOR BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 27. IMMUNOASSAY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

TABLE 28. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

TABLE 29. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 30. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,

2021-2030 (USD BILLION)

TABLE 31. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)

TABLE 32. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 33. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 34. U.S IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 35. U.S IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 36. U.S IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 37. U.S IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 38. CANADA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 39. CANADA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 40. CANADA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 41. CANADA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 42. MEXICO IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 43. MEXICO IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 44. MEXICO IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 45. MEXICO IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 46. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

TABLE 47. EUROPE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 48. EUROPE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 49. EUROPE IMMUNOASSAY MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)

TABLE 50. EUROPE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 51. GERMANY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

TABLE 52. GERMANY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 53. GERMANY IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 54. GERMANY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 55. U.K IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD
BILLION)

TABLE 56. U.K IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

TABLE 57. U.K IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

TABLE 58. U.K IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD
BILLION)

TABLE 59. FRANCE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

TABLE 60. FRANCE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 61. FRANCE IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 62. FRANCE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 63. ITALY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD
BILLION)

TABLE 64. ITALY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

TABLE 65. ITALY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

TABLE 66. ITALY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 67. SPAIN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

TABLE 68. SPAIN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

TABLE 69. SPAIN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030

(USD BILLION)

TABLE 70. SPAIN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030

(USD BILLION)

TABLE 71. ROE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 72. ROE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 73. ROE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 74. ROE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 75. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

TABLE 76. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 77. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 78. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 79. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 80. CHINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 81. CHINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 82. CHINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 83. CHINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 84. INDIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 85. INDIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 86. INDIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 87. INDIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 88. JAPAN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 89. JAPAN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

TABLE 90. JAPAN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

TABLE 91. JAPAN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 92. REST OF APAC IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

TABLE 93. REST OF APAC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 94. REST OF APAC IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 95. REST OF APAC IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

TABLE 96. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

TABLE 97. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 98. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 99. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

TABLE 100. BRAZIL IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

TABLE 101. BRAZIL IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 102. BRAZIL IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 103. BRAZIL IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

TABLE 104. ARGENTINA IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

TABLE 105. ARGENTINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

TABLE 106. ARGENTINA IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

TABLE 107. ARGENTINA IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

TABLE 108. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY

PRODUCT, 2021-2030 (USD BILLION)

TABLE 109. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 110. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 111. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 112. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 113. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 114. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 115. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 116. UAE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 117. UAE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 118. UAE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 119. UAE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 120. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

TABLE 121. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

TABLE 122. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

TABLE 123. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

TABLE 124. SIEMENS HEALTHINEERS: FINANCIALS

TABLE 125. SIEMENS HEALTHINEERS: PRODUCTS & SERVICES

TABLE 126. SIEMENS HEALTHINEERS: RECENT DEVELOPMENTS

TABLE 127. BIOM?RIEUX SA: FINANCIALS

TABLE 128. BIOM?RIEUX SA: PRODUCTS & SERVICES

TABLE 129. BIOM?RIEUX SA: RECENT DEVELOPMENTS

TABLE 130. ABBOTT LABORATORIES: FINANCIALS

TABLE 131. ABBOTT LABORATORIES: PRODUCTS & SERVICES

TABLE 132. ABBOTT LABORATORIES: RECENT DEVELOPMENTS

TABLE 133. DANAHER CORPORATION (BECKMAN COULTER).: FINANCIALS

TABLE 134. DANAHER CORPORATION (BECKMAN COULTER).: PRODUCTS & SERVICES

TABLE 135. DANAHER CORPORATION (BECKMAN COULTER).: RECENT DEVELOPMENTS

TABLE 136. QUIDEL CORPORATION: FINANCIALS

TABLE 137. QUIDEL CORPORATION: PRODUCTS & SERVICES

TABLE 138. QUIDEL CORPORATION: RECENT DEVELOPMENTS

TABLE 139. ORTHO CLINICAL DIAGNOSTICS: FINANCIALS

TABLE 140. ORTHO CLINICAL DIAGNOSTICS: PRODUCTS & SERVICES

TABLE 141. ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS

TABLE 142. SYSMEX CORPORATION: FINANCIALS

TABLE 143. SYSMEX CORPORATION: PRODUCTS & SERVICES

TABLE 144. SYSMEX CORPORATION: DEVELOPMENTS

TABLE 145. BIO-RAD LABORATORIES, INC.: FINANCIALS

TABLE 146. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES

TABLE 147. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS

TABLE 148. F. HOFFMANN-LA ROCHE AG: FINANCIALS

TABLE 149. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES

TABLE 150. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS

TABLE 151. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS

TABLE 152. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES

TABLE 153. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS

Charts

CHART. 1. IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 2. IMMUNOASSAY MARKET VALUE FOR ELISA, BY GEOGRAPHY , 2021-2030 (USD BILLION)

CHART. 3. IMMUNOASSAY MARKET VALUE FOR FLUORESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 4. IMMUNOASSAY MARKET VALUE FOR COLORIMETRIC, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 5. IMMUNOASSAY MARKET VALUE FOR CHEMILUMINESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 6. IMMUNOASSAY MARKET VALUE FOR RAPID TEST, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 7. IMMUNOASSAY MARKET VALUE FOR WESTERN BLOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 8. IMMUNOASSAY MARKET VALUE FOR ELISPOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 9. IMMUNOASSAY MARKET VALUE FOR PCR, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 10. IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)

CHART. 11. IMMUNOASSAY MARKET VALUE FOR REAGENTS & KITS, 2021-2030 (USD BILLION)

CHART. 12. IMMUNOASSAY MARKET VALUE FOR ANALYZERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 13. IMMUNOASSAY MARKET VALUE FOR SOFTWARE SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 14. IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 15. IMMUNOASSAY MARKET VALUE FOR INFECTIOUS DISEASE, 2021-2030 (USD BILLION)

CHART. 16. IMMUNOASSAY MARKET VALUE FOR ENDOCRINOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 17. IMMUNOASSAY MARKET VALUE FOR CARDIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 18. IMMUNOASSAY MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 19. IMMUNOASSAY MARKET VALUE FOR HEMATOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 20. IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 21. IMMUNOASSAY MARKET VALUE FOR HOSPITALS, 2021-2030 (USD BILLION)

CHART. 22. IMMUNOASSAY MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 23. IMMUNOASSAY MARKET VALUE FOR BLOOD BANKS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 24. IMMUNOASSAY MARKET VALUE FOR ACADEMIC RESEARCH CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 25. IMMUNOASSAY MARKET VALUE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 26. IMMUNOASSAY MARKET VALUE FOR BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)

CHART. 27. IMMUNOASSAY MARKET VALUE FOR OTHERS, BY GEOGRAPHY,

2021-2030 (USD BILLION)

CHART. 28. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 29. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 30. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 31. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)

CHART. 32. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 33. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 34. U.S IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 35. U.S IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 36. U.S IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 37. U.S IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 38. CANADA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 39. CANADA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 40. CANADA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 41. CANADA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 42. MEXICO IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 43. MEXICO IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 44. MEXICO IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 45. MEXICO IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 46. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 47. EUROPE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 48. EUROPE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 49. EUROPE IMMUNOASSAY MARKET VALUE, END USE INDUSTRIES,
2021-2030 (USD BILLION)

CHART. 50. EUROPE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

CHART. 51. GERMANY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 52. GERMANY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 53. GERMANY IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

CHART. 54. GERMANY IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

CHART. 55. U.K IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD
BILLION)

CHART. 56. U.K IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

CHART. 57. U.K IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

CHART. 58. U.K IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD
BILLION)

CHART. 59. FRANCE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 60. FRANCE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 61. FRANCE IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

CHART. 62. FRANCE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

CHART. 63. ITALY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 64. ITALY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030
(USD BILLION)

CHART. 65. ITALY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

CHART. 66. ITALY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030

(USD BILLION)

CHART. 67. SPAIN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030

(USD BILLION)

CHART. 68. SPAIN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030

(USD BILLION)

CHART. 69. SPAIN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030

(USD BILLION)

CHART. 70. SPAIN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030

(USD BILLION)

CHART. 71. ROE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 72. ROE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 73. ROE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 74. ROE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 75. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)

CHART. 76. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 77. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 78. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 79. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 80. CHINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 81. CHINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 82. CHINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 83. CHINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 84. INDIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 85. INDIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 86. INDIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

CHART. 87. INDIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

CHART. 88. JAPAN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 89. JAPAN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 90. JAPAN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030
(USD BILLION)

CHART. 91. JAPAN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

CHART. 92. REST OF APAC IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

CHART. 93. REST OF APAC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 94. REST OF APAC IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

CHART. 95. REST OF APAC IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

CHART. 96. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

CHART. 97. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 98. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

CHART. 99. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY END USER,
2021-2030 (USD BILLION)

CHART. 100. BRAZIL IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030
(USD BILLION)

CHART. 101. BRAZIL IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,
2021-2030 (USD BILLION)

CHART. 102. BRAZIL IMMUNOASSAY MARKET VALUE, BY APPLICATION,
2021-2030 (USD BILLION)

CHART. 103. BRAZIL IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030
(USD BILLION)

CHART. 104. ARGENTINA IMMUNOASSAY MARKET VALUE, BY PRODUCT,
2021-2030 (USD BILLION)

CHART. 105. ARGENTINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY,

2021-2030 (USD BILLION)

CHART. 106. ARGENTINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 107. ARGENTINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 108. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 109. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 110. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 111. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 112. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 113. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 114. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 115. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 116. UAE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 117. UAE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 118. UAE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 119. UAE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 120. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)

CHART. 121. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)

CHART. 122. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)

CHART. 123. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)

CHART. 124. SIEMENS HEALTHINEERS: FINANCIALS

CHART. 125. SIEMENS HEALTHINEERS: PRODUCTS & SERVICES

CHART. 126. SIEMENS HEALTHINEERS: RECENT DEVELOPMENTS
CHART. 127. BIOM?RIEUX SA: FINANCIALS
CHART. 128. BIOM?RIEUX SA: PRODUCTS & SERVICES
CHART. 129. BIOM?RIEUX SA: RECENT DEVELOPMENTS
CHART. 130. ABBOTT LABORATORIES: FINANCIALS
CHART. 131. ABBOTT LABORATORIES: PRODUCTS & SERVICES
CHART. 132. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
CHART. 133. DANAHER CORPORATION (BECKMAN COULTER).: FINANCIALS
CHART. 134. DANAHER CORPORATION (BECKMAN COULTER).: PRODUCTS & SERVICES
CHART. 135. DANAHER CORPORATION (BECKMAN COULTER).: RECENT DEVELOPMENTS
CHART. 136. QUIDEL CORPORATION: FINANCIALS
CHART. 137. QUIDEL CORPORATION: PRODUCTS & SERVICES
CHART. 138. QUIDEL CORPORATION: RECENT DEVELOPMENTS
CHART. 139. ORTHO CLINICAL DIAGNOSTICS: FINANCIALS
CHART. 140. ORTHO CLINICAL DIAGNOSTICS: PRODUCTS & SERVICES
CHART. 141. ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
CHART. 142. SYSMEX CORPORATION: FINANCIALS
CHART. 143. SYSMEX CORPORATION: PRODUCTS & SERVICES
CHART. 144. SYSMEX CORPORATION: DEVELOPMENTS
CHART. 145. BIO-RAD LABORATORIES, INC.: FINANCIALS
CHART. 146. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
CHART. 147. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
CHART. 148. F. HOFFMANN-LA ROCHE AG: FINANCIALS
CHART. 149. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES
CHART. 150. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS
CHART. 151. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS
CHART. 152. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES
CHART. 153. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS

I would like to order

Product name: Immunoassay Market based on by Product (Reagents and Kits, Analyzers/Instruments, Software and Services), Technology [Radioimmunoassay (RIA), Enzyme-linked Immunosorbent Assay (ELISA), Enzyme-linked Fluorescent Assay (ELFA), Chemiluminescence Immunoassay (CLIA), Rapid Test, Others], Indication (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Diseases, Autoimmune Diseases, Others), End User (Hospitals, Clinical Laboratories, Blood Banks, Pharmaceutical and Biotechnology Companies, Academic) and Regional Outlook– Global Forecast up to 2030

Product link: <https://marketpublishers.com/r/l80C81077EA5EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l80C81077EA5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970